$BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Healthcare
Sector
Biotechnology
Industry
Ryan Cohlhepp
CEO
55
Employees
$21.98
Current Price
$896.78M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 3 | $488,461.92 | 24,200 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 5 | $742,110.67 | 36,700 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 10 | $1,721,291.32 | 78,900 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 27 | $4,305,404.08 | 216,510 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 21, 2026 | Hyep Ivan Chief Financial Officer | Sale | 9,200 | $20.42 | $187,883.32 | View Details |
| May 18, 2026 | Mazumdar Claire Director | Sale | 12,022 | $19.96 | $239,981.96 | View Details |
| May 18, 2026 | Mazumdar Claire Director | Sale | 2,978 | $20.35 | $60,596.64 | View Details |
| May 15, 2026 | Cohlhepp Ryan Director | Sale | 4,500 | $20.29 | $91,313.55 | View Details |
| May 15, 2026 | Cohlhepp Ryan Director | Sale | 8,000 | $20.29 | $162,335.20 | View Details |
| Apr 27, 2026 | Raben David Chief Medical Officer | Sale | 5,500 | $22.88 | $125,830.10 | View Details |
| Apr 21, 2026 | Hyep Ivan Chief Financial Officer | Sale | 9,200 | $23.00 | $211,613.80 | View Details |
| Apr 20, 2026 | Mazumdar Claire Director | Sale | 15,000 | $23.61 | $354,145.50 | View Details |
| Apr 15, 2026 | Cohlhepp Ryan Director | Sale | 8,000 | $23.01 | $184,058.40 | View Details |
| Apr 15, 2026 | Cohlhepp Ryan Director | Sale | 4,500 | $23.01 | $103,532.85 | View Details |
| Mar 25, 2026 | Raben David Chief Medical Officer | Sale | 5,500 | $18.95 | $104,229.40 | View Details |
| Mar 23, 2026 | Hyep Ivan Chief Financial Officer | Sale | 9,200 | $18.52 | $170,348.12 | View Details |
| Mar 18, 2026 | Mazumdar Claire Director | Sale | 6,499 | $18.84 | $122,414.51 | View Details |
| Mar 19, 2026 | Mazumdar Claire Director | Sale | 6,905 | $18.78 | $129,704.90 | View Details |
| Mar 20, 2026 | Mazumdar Claire Director | Sale | 1,596 | $18.95 | $30,246.27 | View Details |
| Mar 16, 2026 | Cohlhepp Ryan Director | Sale | 4,500 | $19.66 | $88,456.95 | View Details |
| Mar 16, 2026 | Cohlhepp Ryan Director | Sale | 8,000 | $19.66 | $157,256.80 | View Details |
| Mar 9, 2026 | Mazumdar Claire Director | Sale | 36,766 | $19.17 | $704,657.16 | View Details |
| Mar 4, 2026 | Mazumdar Claire Director | Sale | 2,631 | $18.73 | $49,288.63 | View Details |
| Mar 6, 2026 | Mazumdar Claire Director | Sale | 3,817 | $18.75 | $71,571.80 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.67
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$ACET โ Adicet Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$ETNB โ 89bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$ARTV โ Artiva Biotherapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$JANX โ Janux Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.